Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Data from University of Halle-Wittenberg advance knowledge in breast cancer
January 15th, 2008
According to a study from Halle, Germany, "According to established clinicopathological factors, approximately 70% of breast cancer patients without axillary node involvement belong to the group of patients with an intermediate risk of recurrence. In such patients with endocrine responsive disease, the current guidelines suggest either adjuvant chemo-endocrine therapy or endocrine therapy alone." "The challenge is therefore to identify those patients who will not need adjuvant chemotherapy due to their very low risk of recurrence. The plasminogen activator system is a complex system with multiple functions, e.g. cell invasion, angiogenesis and senescence, in a variety...
Source: Cancer Weekly (2008-01-15)
|
